EuroBiotech: More Articles of Note


> MorphoSys received FDA breakthrough designation for MOR208 in diffuse large B-cell lymphoma. The FDA awarded the regulatory status to the anti-CD19 antibody on the strength of preliminary data from a phase 2 Revlimid combination trial. Release

> Nicox struck a deal with Re-Vana Therapeutics. The partners will look into combining Nicox’s stand-alone nitric oxide-donors with Re-Vana's biodegradable drug delivery platform. Statement

> UniQure moved to capitalize on the positive response to its pipeline switch up with a stock offering. The gene therapy specialist is offering 5 million shares, positioning it to pull in close to $100 million at its recently-risen stock price. Release

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.

> Ergomed reported top-line data from a phase 2 trial of its coagulant PeproStat. The drug cut time to hemostasis by 1.55 minutes compared to standard of care, a statistically-significant difference that resulted in the trial hitting its primary endpoint. Statement

> Mologen received a $10 million investment from Global Corporate Finance. The money equips Mologen to push ahead with its lefitolimod-focused strategy. Lefitolimod is a clinical-phase TLR9 agonist. Release 

> Transgene reported data from a phase 1/1b trial of its hepatitis B immunotherapy TG1050. Two-fifths of participants experienced drug-related adverse events but none were more severe than grade 2. Most of the adverse events were injection site reactions. Statement